These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16600982)

  • 21. The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.
    Mol L; Ottevanger PB; Koopman M; Punt CJ
    Eur J Cancer; 2016 Oct; 66():138-43. PubMed ID: 27573427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
    Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
    Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients.
    Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AK; Tang NL; Chu CM; Hui J; Lee KF; Yu S; Yeo W
    Qual Life Res; 2019 Sep; 28(9):2597-2607. PubMed ID: 31037590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
    Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
    Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
    Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocellular carcinoma in uremic patients: is there evidence for an increased risk of mortality?
    Lee YH; Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Huo TI
    J Gastroenterol Hepatol; 2013 Feb; 28(2):348-56. PubMed ID: 23190248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
    Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL
    Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
    Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
    J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular Carcinoma.
    Kim GA; Kim HI; Chang S; An J; Lee D; Lee HC; Han S; Shim JH
    Am J Clin Oncol; 2019 Jul; 42(7):555-563. PubMed ID: 31135382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors of overall well-being using the EORTC QLQ-C15-PAL extracted from the EORTC QLQ-C30.
    Lam K; Zeng L; Zhang L; Tseng LM; Hou MF; Fairchild A; Vassiliou V; Jesus-Garcia R; Alm El-Din MA; Kumar A; Forges F; Chie WC; Sahgal A; Poon M; Chow E
    J Palliat Med; 2013 Apr; 16(4):402-8. PubMed ID: 23458649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
    Chow PK; Tai BC; Tan CK; Machin D; Win KM; Johnson PJ; Soo KC;
    Hepatology; 2002 Nov; 36(5):1221-6. PubMed ID: 12395333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma.
    Yu Y; Lang QB; Chen Z; Li B; Yu CQ; Zhu DZ; Huang XQ; Zhai XF; Ling CQ
    Chin Med J (Engl); 2009 Sep; 122(17):1990-5. PubMed ID: 19781383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline quality of life predicts overall survival in patients with mCRPC treated with
    Frantellizzi V; De Feo MS; Di Rocco A; Pontico M; Pani A; Farcomeni A; Cosma L; Lazri J; De Vincentis G
    Hell J Nucl Med; 2020; 23(1):12-20. PubMed ID: 32222727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma.
    Wu MT; He SY; Chen SL; Li LF; He ZQ; Zhu YY; He X; Chen H
    BMC Cancer; 2019 Jun; 19(1):538. PubMed ID: 31164099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can changes in health related quality of life scores predict survival in stages III and IV colorectal cancer?
    Braun DP; Gupta D; Grutsch JF; Staren ED
    Health Qual Life Outcomes; 2011 Aug; 9():62. PubMed ID: 21812962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life in patients with hepatocellular carcinoma received surgical resection.
    Lee LJ; Chen CH; Yao G; Chung CW; Sheu JC; Lee PH; Tsai YJ; Wang JD
    J Surg Oncol; 2007 Jan; 95(1):34-9. PubMed ID: 17192864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
    Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
    J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Labenz C; Prenosil V; Koch S; Huber Y; Marquardt JU; Schattenberg JM; Galle PR; Weinmann A; Wörns MA
    Dig Dis; 2018; 36(1):78-88. PubMed ID: 28675895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.